titanium has been researched along with 4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, J; Fang, Z; Kang, Y; Li, C; Li, L; Lin, X; Liu, Q; Pu, R; Qin, A; Shao, S; Wu, Z; Yuan, G; Zhao, J | 1 |
1 other study(ies) available for titanium and 4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide
| Article | Year |
|---|---|
Vx-11e protects against titanium-particle-induced osteolysis and osteoclastogenesis by supressing ERK activity.
Topics: Animals; Cell Survival; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Male; Mice; Mice, Inbred C57BL; Osteoclasts; Osteogenesis; Particle Size; Protective Agents; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Titanium | 2019 |